Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation

An analysis of the United network for organ sharing database

Gundeep S. Dhillon, Joseph Levitt, Hari Mallidi, Vincent G. Valentine, Meera R. Gupta, Ramachandra Sista, David Weill

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND.: The availability of suitable lung and heart-lung allografts for transplantation remains poor. Accepting organs from donors with positive serological studies for hepatitis B could potentially expand the donor pool. The aim of this study was to assess the impact of donor hepatitis B core antibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients. METHODS.: Using United Network for Organ Sharing/Organ Procurement and Transplantation Network data, we compared outcomes of 13,233 recipients of HBcAb negative organs with 333 recipients of HBcAb positive donor organs. RESULTS.: We found that the unadjusted 1-year survival of recipients of HBcAb positive donor was worse, but there was no difference in survival after adjusting for baseline donor and recipient differences. On multivariate analysis, recipient and donor age, procedure type, era of transplant, baseline medical condition, diagnosis, and donor hepatitis C antibody status impacted 1-and 5-year survival. However, donor HBcAb status did not impact 1-or 5-year survival posttransplant. CONCLUSIONS.: Lung and heart-lung allografts from HBcAb positive donors may be safely used, which would increase the number of transplants performed without compromising recipient outcomes.

Original languageEnglish (US)
Pages (from-to)842-846
Number of pages5
JournalTransplantation
Volume88
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Heart-Lung Transplantation
Hepatitis B Antibodies
Tissue Donors
Databases
Lung
Survival
Allografts
Transplants
Hepatitis C Antibodies
Tissue and Organ Procurement
Organ Transplantation
Hepatitis B
Multivariate Analysis

Keywords

  • Donor infection
  • Hepatitis B.
  • Lung transplantation
  • Outcomes

ASJC Scopus subject areas

  • Transplantation

Cite this

Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation : An analysis of the United network for organ sharing database. / Dhillon, Gundeep S.; Levitt, Joseph; Mallidi, Hari; Valentine, Vincent G.; Gupta, Meera R.; Sista, Ramachandra; Weill, David.

In: Transplantation, Vol. 88, No. 6, 2009, p. 842-846.

Research output: Contribution to journalArticle

Dhillon, Gundeep S. ; Levitt, Joseph ; Mallidi, Hari ; Valentine, Vincent G. ; Gupta, Meera R. ; Sista, Ramachandra ; Weill, David. / Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation : An analysis of the United network for organ sharing database. In: Transplantation. 2009 ; Vol. 88, No. 6. pp. 842-846.
@article{19a7fd3082574cb4a1ed4c4cc7106bb0,
title = "Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: An analysis of the United network for organ sharing database",
abstract = "BACKGROUND.: The availability of suitable lung and heart-lung allografts for transplantation remains poor. Accepting organs from donors with positive serological studies for hepatitis B could potentially expand the donor pool. The aim of this study was to assess the impact of donor hepatitis B core antibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients. METHODS.: Using United Network for Organ Sharing/Organ Procurement and Transplantation Network data, we compared outcomes of 13,233 recipients of HBcAb negative organs with 333 recipients of HBcAb positive donor organs. RESULTS.: We found that the unadjusted 1-year survival of recipients of HBcAb positive donor was worse, but there was no difference in survival after adjusting for baseline donor and recipient differences. On multivariate analysis, recipient and donor age, procedure type, era of transplant, baseline medical condition, diagnosis, and donor hepatitis C antibody status impacted 1-and 5-year survival. However, donor HBcAb status did not impact 1-or 5-year survival posttransplant. CONCLUSIONS.: Lung and heart-lung allografts from HBcAb positive donors may be safely used, which would increase the number of transplants performed without compromising recipient outcomes.",
keywords = "Donor infection, Hepatitis B., Lung transplantation, Outcomes",
author = "Dhillon, {Gundeep S.} and Joseph Levitt and Hari Mallidi and Valentine, {Vincent G.} and Gupta, {Meera R.} and Ramachandra Sista and David Weill",
year = "2009",
doi = "10.1097/TP.0b013e3181b4e1fd",
language = "English (US)",
volume = "88",
pages = "842--846",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation

T2 - An analysis of the United network for organ sharing database

AU - Dhillon, Gundeep S.

AU - Levitt, Joseph

AU - Mallidi, Hari

AU - Valentine, Vincent G.

AU - Gupta, Meera R.

AU - Sista, Ramachandra

AU - Weill, David

PY - 2009

Y1 - 2009

N2 - BACKGROUND.: The availability of suitable lung and heart-lung allografts for transplantation remains poor. Accepting organs from donors with positive serological studies for hepatitis B could potentially expand the donor pool. The aim of this study was to assess the impact of donor hepatitis B core antibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients. METHODS.: Using United Network for Organ Sharing/Organ Procurement and Transplantation Network data, we compared outcomes of 13,233 recipients of HBcAb negative organs with 333 recipients of HBcAb positive donor organs. RESULTS.: We found that the unadjusted 1-year survival of recipients of HBcAb positive donor was worse, but there was no difference in survival after adjusting for baseline donor and recipient differences. On multivariate analysis, recipient and donor age, procedure type, era of transplant, baseline medical condition, diagnosis, and donor hepatitis C antibody status impacted 1-and 5-year survival. However, donor HBcAb status did not impact 1-or 5-year survival posttransplant. CONCLUSIONS.: Lung and heart-lung allografts from HBcAb positive donors may be safely used, which would increase the number of transplants performed without compromising recipient outcomes.

AB - BACKGROUND.: The availability of suitable lung and heart-lung allografts for transplantation remains poor. Accepting organs from donors with positive serological studies for hepatitis B could potentially expand the donor pool. The aim of this study was to assess the impact of donor hepatitis B core antibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients. METHODS.: Using United Network for Organ Sharing/Organ Procurement and Transplantation Network data, we compared outcomes of 13,233 recipients of HBcAb negative organs with 333 recipients of HBcAb positive donor organs. RESULTS.: We found that the unadjusted 1-year survival of recipients of HBcAb positive donor was worse, but there was no difference in survival after adjusting for baseline donor and recipient differences. On multivariate analysis, recipient and donor age, procedure type, era of transplant, baseline medical condition, diagnosis, and donor hepatitis C antibody status impacted 1-and 5-year survival. However, donor HBcAb status did not impact 1-or 5-year survival posttransplant. CONCLUSIONS.: Lung and heart-lung allografts from HBcAb positive donors may be safely used, which would increase the number of transplants performed without compromising recipient outcomes.

KW - Donor infection

KW - Hepatitis B.

KW - Lung transplantation

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=70350552091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350552091&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e3181b4e1fd

DO - 10.1097/TP.0b013e3181b4e1fd

M3 - Article

VL - 88

SP - 842

EP - 846

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -